Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Diagnosed incident cases of chronic myeloid leukemia to reach 17,500 by 2030 across 8MM, forecasts GlobalData

The diagnosed incident cases of chronic myeloid leukemia (CML) across the eight major markets (*8MM) are projected to increase from 15,500 cases in 2020 to 17,500 in 2030, equating to an annual growth rate (AGR) of 1.32%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Chronic Myeloid Leukemia: Epidemiology Forecast to 2030’, […]
Read more

Key pharma players collaborate with tech companies in Singapore to stay competitive, observes GlobalData

AstraZeneca Singapore signed a contract with technology partners Respiree, OncoShot, Thermaiscan, Ubie and Hewlett Packard Enterprise in November 2021 to offer new digital healthcare solutions for chronic conditions such as cancer, diabetes, heart failure, and respiratory diseases to patients. Against this backdrop, pharma companies are under constant pressure to innovate and stay competitive. As a […]
Read more

Primary open angle glaucoma total prevalent cases set to reach 8.84 million in the 7MM by 2030, driven by an aging population, more comorbid conditions, and delayed access to health care facilities, says GlobalData

The burden of total prevalent cases (diagnosed and undiagnosed) of primary open angle glaucoma (POAG) is expected to increase at an annual growth rate (AGR) of 2% from around 7.3 million cases in 2020 to 8.84 million in 2030 in the seven major markets (7MM*), according to GlobalData. The leading data and analytics company notes […]
Read more

Impending regulatory decisions in the atopic dermatitis market, says GlobalData

The FDA has yet to come to a conclusion on the approval of Lilly/Incyte’s JAK1/2 inhibitor Olumiant (baricitinib), AbbVie’s JAK 1 inhibitor Rinvoq (upadacitinib), and Pfizer’s, JAK 1 inhibitor Cibinqo (abrocitinib), the leading data and analytics company notes that competition will likely heighten once these JAK inhibitors become available. Ramla Salad, Pharma Analyst at GlobalData, […]
Read more

Successful FDA EUA of first indigenous combo mAb therapy may boost China’s credibility, says GlobalData

The National Medical Products Administration (NMPA) of China has recently approved Brii Biosciences’ amubarvimab/romlusevimab combination as the first COVID-19 neutralizing antibody combination therapy in the country. The company is currently pursuing emergency use authorization (EUA) from the FDA. If approved, it becomes the first combo antibody therapy from a Chinese company to gain entry into […]
Read more

Stiff competition expected in BCMA CAR-T therapies for multiple myeloma treatment in Japan, says GlobalData

Janssen Pharmaceutical has recently filed for B-cell maturation antigen (BCMA) CAR-T therapy Cilta-cel in Japan. Earlier in March 2021, Bristol-Myers Squibb (BMS) filed for the first BCMA CAR-T therapy, idecabtagene vicleucel in the country. Following approval by the Japanese regulatory authority, BMS will have the first-mover advantage. However, stiff competition is expected for multiple myeloma […]
Read more

Key players in Japan lupus market have significant scope to improve presence in digital space, says GlobalData

Pharma companies offer support to Japanese patients and rheumatologists with systemic lupus erythematosus (SLE or lupus) through unbranded and branded digital channels providing disease support tools. However, there is a significant opportunity for key players such as GSK and AstraZeneca to improve their presence in the digital space, says GlobalData, a leading data and analytics […]
Read more

Positive phase III data will give Neurocrine’s Ingrezza dominant position in Huntington’s disease market, says GlobalData

Neurocrine Biosciences has recently announced that its pipeline asset, Ingrezza (valbenazine), achieved the primary endpoint of reducing the symptoms of chorea (involuntary muscle movements) associated with Huntington’s disease (HD) in the Phase III clinical trial, KINECT-HD (NCT04102579). This will propel Ingrezza into a dominant position in the HD market, due to its convenient once-daily dosing […]
Read more

Hypoglycemia rescue is a saturated market, but opportunity remains for targeted preventative treatments, according to GlobalData

The current treatments for hypoglycemia (also known as low blood sugar) are meeting practitioners’ needs well, and there are very few areas of improvement, according to key opinion leaders (KOLs) interviewed by GlobalData. The leading data and analytics company noted that the biggest issue KOLs want addressing was the role insulin therapies play in the […]
Read more

Clinical trial process would be improved with digital transformation, say 35% of healthcare professionals, according to a GlobalData survey

A total 35% of healthcare professionals worldwide believe that digital transformation — involving the use of technologies such as AI, big data, cloud computing, application programming interfaces (API) and digital platforms — would improve both pre-clinical and clinical trials, according to a survey by GlobalData. The leading data and analytics company notes that drug developers […]
Read more

Zydus Cadila Desidustat better positioned to get first to market advantage within HIF-PHI class in India, says GlobalData

New class of treatment, especially hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to treat patients with anemia from chronic kidney disease (CKD), is gaining traction in countries where drugs of this class are approved. India is yet to approve its first HIF-PH inhibitor drug to treat anemia associated with chronic kidney disease. However, Zydus Cadila’s […]
Read more
1 … 52 53 54 55 56 … 108